Войти в систему Зарегистрироваться бесплатно

NeuroVive Pharmaceutical AB Долг / собственный капитал

Что обозначает Долг / собственный капитал в NeuroVive Pharmaceutical AB?

Долг / собственный капитал NeuroVive Pharmaceutical AB является 0.42

Какое определение для Долг / собственный капитал?



Соотношение долга к собственному капиталу - это финансовое соотношение, показывающее относительную пропорцию собственного капитала и долга, используемых для финансирования активов компании.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Долг / собственный капитал компаний в Miscellaneous сектор на LSE по сравнению с NeuroVive Pharmaceutical AB

Что делает NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Компании с долг / собственный капитал похож на NeuroVive Pharmaceutical AB